Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Debt Repayments (2021 - 2022)

ARS Pharmaceuticals (SPRY) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $6.0 million as the latest value for Q4 2022.

  • Quarterly Long-Term Debt Repayments rose 513.18% to $6.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Sep 2023, up 61.01% year-over-year, with the annual reading at $8.7 million for FY2022, 377.77% up from the prior year.
  • Long-Term Debt Repayments hit $6.0 million in Q4 2022 for ARS Pharmaceuticals, up from $909000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $6.0 million in Q4 2022 to a low of $350000.0 in Q1 2021.